Replies to post #307419 on Amarin Corp Plc (AMRN)

[HinduKush]

They must have at least 1600 prior event CAD patients on Vascepa for a yr who haven’t had Covid ... to match against the remaining 14,400 CAD with prior events ... no Covid and no Vascepa
Total population in study being 16,000

So why do they put 14,400 in the prior CAD event & NO COVID NO Vascepa arm
versus 1600 in the prior CAD, NO COVID, and VASCEPA Rx arm

Normally we would randomize 1:1 not 10:1 but was the cost of Vascepa for the trial the limiting factor?

BUT here all the patients had a prior CAD event so it is definitely indicated per R-IT criteria to treat all with Vascepa. The main R-IT and R-IT REVASC analysis showed 25-30% reductions in first and subsequent revascularizations not to mention other CV events like MI Stroke, CV death etc..
Is it ethical to even have an arm that is:PRIOR CAD event (& NO COVID) NO Vascepa?
Not in my book...
HK